
High Force Research appoints Nathalie Huther as chief commercial officer
Ella Day | April 8, 2025 | Appointment | Manufacturing and Production, Research and Development | Corporate, High Force Research, cco, manufacturing and production
High Force Research has announced that it has appointed Nathalie Huther as its first chief commercial officer (CCO) following the company’s recent management buyout (MBO). This forms an important part of its business development and market expansion strategy.
Huther will lead High Force’s research commercial strategy, and brings a wealth of experience in commercial leadership in the chemical, pharma and biotech service sectors. In particular, she focused on revenue growth and forming strategic partnerships. Previous companies include Sai Life Sciences, Nanoform, Arcinova, Sigma-Aldrich and SiliCycle.
UK-based High Force Research is a chemical R&D and manufacturing service provider, offering a range of materials and solutions across pharma, biotech and chemical industries.
Huther commented on the appointment: “I am delighted to join High Force Research at such a pivotal time.” She added: I look forward to building on this foundation, strengthening existing partnerships and identifying new opportunities for growth.”
Chief executive officer at High Force, Tristan Sillars, said: “We are thrilled to welcome Nathalie to the team. Nathalie’s expertise will be invaluable as we focus on expanding our commercial reach and delivering even greater value to our clients. The recent MBO has positioned us for growth, and Nathalie will play a key role in driving that forward.”
Ella Day
8/4/25
Related Content

Rotzinger launches modular filling and capping platform for over-the-counter products
Rotzinger PharmaPack has launched a new filling and capping platform called VarioFill, designed to handle …

Long term BMS exec Johanna Mercier joins Gilead as new Chief Commercial Officer
Gilead Sciences have said Bristol-Myers Squibb exec Johanna Mercier will be the firm’s new Chief …

Pfizer set to develop new $200 million site
Pfizer plans to expand its operations in St. Louis, Missouri, by developing a $200 million …






